Source : EuropeanMarkets
Said Darwazah, Chief Executive Officer of Hikma, said:
“We have had an excellent start to the year. Our financial results are in line with expectations and we are making strong strategic progress across the Group.
The acquisition of Roxane, agreed in July, will transform our business in the US, adding complementary and well differentiated products, an attractive pipeline, proven R&D capabilities and greater overall scale. It also provides an excellent opportunity to expand our product portfolio in other markets, particularly the MENA region.
Bedford is now well integrated, we have launched the first of their generic injectable products and we are confident that we will continue to bring a steady stream of these products back to the market. The addition of Bedford and Roxane to our US businesses will enable us to capture growth opportunities in more specialised segments of the US generics market.
Our businesses in MENA are performing very well and we are strongly positioned for continued growth. Our partnership with Vitabiotics, announced today, will leverage our marketing and sales capabilities in MENA and broaden our product portfolio, and is a great example of how we are implementing our growth strategy in the region.
We have taken important strategic steps this year and we are very excited about the opportunities these bring to the Group. Across our geographies, we have strong market positions, we are executing well and we are very confident in the outlook for 2015 and beyond.”
H1 2015 financial highlights
. Group revenue of $709 million, in line with H1 2014 in constant currency, or down 4% on a reported basis, with good performances from Branded and Injectables, offset by the expected decline in specific market opportunities in Generics
. Full year Group revenue guidance maintained at around 6% growth in constant currency, or 2% on a reported basis
. Group adjusted operating profit of $204 million, compared with $244 million in H1 2014,
. Basic EPS of 67.3 cents per share, down 21%
. Interim dividend of 11.0 cents per share, in line with total dividend paid in H1 2014
H1 2015 strategic highlights
. Roxane acquisition will transform Hikma’s US business, establishing Hikma as the sixth largest US generics company
. Successful integration of Bedford is delivering new approvals for US Injectables
. Inaugural bond issue raised $500 million, providing financial flexibility to support future growth
. Partnership with Vitabiotics, announced today, broadens Hikma’s MENA portfolio with leading OTC brands
. New product introductions across all countries and markets – launched 40 products and received 118 product approvals, expanding and enhancing Hikma’s global product portfolio
Source : Press Release Hikma Pharmaceuticals, London (UK), 19 August 2015
“We have had an excellent start to the year. Our financial results are in line with expectations and we are making strong strategic progress across the Group.
The acquisition of Roxane, agreed in July, will transform our business in the US, adding complementary and well differentiated products, an attractive pipeline, proven R&D capabilities and greater overall scale. It also provides an excellent opportunity to expand our product portfolio in other markets, particularly the MENA region.
Bedford is now well integrated, we have launched the first of their generic injectable products and we are confident that we will continue to bring a steady stream of these products back to the market. The addition of Bedford and Roxane to our US businesses will enable us to capture growth opportunities in more specialised segments of the US generics market.
Our businesses in MENA are performing very well and we are strongly positioned for continued growth. Our partnership with Vitabiotics, announced today, will leverage our marketing and sales capabilities in MENA and broaden our product portfolio, and is a great example of how we are implementing our growth strategy in the region.
We have taken important strategic steps this year and we are very excited about the opportunities these bring to the Group. Across our geographies, we have strong market positions, we are executing well and we are very confident in the outlook for 2015 and beyond.”
H1 2015 financial highlights
. Group revenue of $709 million, in line with H1 2014 in constant currency, or down 4% on a reported basis, with good performances from Branded and Injectables, offset by the expected decline in specific market opportunities in Generics
. Full year Group revenue guidance maintained at around 6% growth in constant currency, or 2% on a reported basis
. Group adjusted operating profit of $204 million, compared with $244 million in H1 2014,
. Basic EPS of 67.3 cents per share, down 21%
. Interim dividend of 11.0 cents per share, in line with total dividend paid in H1 2014
H1 2015 strategic highlights
. Roxane acquisition will transform Hikma’s US business, establishing Hikma as the sixth largest US generics company
. Successful integration of Bedford is delivering new approvals for US Injectables
. Inaugural bond issue raised $500 million, providing financial flexibility to support future growth
. Partnership with Vitabiotics, announced today, broadens Hikma’s MENA portfolio with leading OTC brands
. New product introductions across all countries and markets – launched 40 products and received 118 product approvals, expanding and enhancing Hikma’s global product portfolio